Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.

British journal of haematology - 1 Oct 2016

Beauverd Yan, Alimam Samah, McLornan Donal P, Radia Deepti H, Harrison Claire N

Abstract excerpt

Myelofibrosis (MF) is a rare haematopoietic disorder, commonly diagnosed in the 6th decade: less than 20% are diagnosed before the age of 50 years. In this retrospective study we included all patients given a diagnosis of World Health Organization-defined primary or secondary MF when aged ≤50 years. Forty-three patients with a median age of 43 years were included. Median follow up was 44 months. Twenty-two (51%)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abnormal Karyotype
Share to Anemia
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Leukocytosis

Share to Patient Outcome Assessment

Share to Primary Myelofibrosis

Share to Thrombocytopenia

Source

Identifiers

PMID: 27293069
DOI: 10.1111/bjh.14173

Genes

CALR
JAK2
MPL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.PMID 27293069Read ↗

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.Semantic proximity Read ↗

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.Semantic proximity Read ↗

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.Semantic proximity Read ↗

Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.Semantic proximity Read ↗

Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.Semantic proximity Read ↗

Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Semantic proximity Read ↗

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.Semantic proximity Read ↗

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectivesSemantic proximity Read ↗

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.Semantic proximity Read ↗

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.Semantic proximity Read ↗

Characterization of myeloproliferative neoplasms in the paediatric and young adult population.Semantic proximity Read ↗

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.